Mauna Kea Technologies Provides Update on Safeguard Proceedings, Strategic Discussions and Operational Progress
Mauna Kea Technologies (Euronext Growth: ALMKT), inventor of Cellvizio®, the multidisciplinary probe and needle-based confocal laser endomicroscopy (p/nCLE) platform, provides an update on the safeguard proceedings initiated on March 31, 2025 1, as well as on the progress of its strategic discussions and operational developments. This announcement is part of the Company's commitment to maintaining ongoing transparency with its shareholders and partners during the ongoing process.
Since the initiation of this safeguard proceedings, the Company has engaged in constructive discussions with its financial partners to identify the most appropriate options for achieving a sustainable solution to the current situation.
In parallel, the Company is actively pursuing the exclusive negotiations announced on April 1 st, 2025, with a major healthcare player, aiming to finalize a licensing agreement for Cellvizio® technology in a high-potential therapeutic area. These discussions are progressing constructively and could represent a major strategic milestone for the Company's clinical and commercial development.
On the operational front, Mauna Kea Technologies is experiencing strong momentum with its CellTolerance franchise. The symbolic milestone of 1,500 procedures has been surpassed, demonstrating the growing adoption of the technology. Several new accounts have recently been onboarded, including prestigious institutions that form a solid foundation for future growth. Among them, a leading center in the United States has already performed over 100 procedures in just a few months and continues to show an upward trend in usage. The Company plans to continue updating on these clinical and commercial advancements in the coming weeks.
Finally, Mauna Kea Technologies is actively engaged with several investors to secure the financial visibility required for the safeguard proceedings and the finalization of licensing agreement. These discussions aim to provide the Company with the resources required to execute its long-term growth strategy.
Sacha Loiseau, Ph.D., Chairman and Chief Executive Officer of Mauna Kea Technologies, stated: "We are navigating this transition period with full determination and remain strongly committed to equipping the Company for future growth. Our commercial outlook is becoming more tangible each day, both for CellTolerance and our pancreatic cyst application, which are increasingly supported by clinical data and a clear enthusiasm among physicians and patients. The safeguard proceedings provide us with a protective framework ideal for negotiating with our stakeholders and preparing for the Company's redeployment on solid foundations. I am very pleased with the dedication of our teams and am fully committed to shaping a new chapter of strong value creation for the Company. Cellvizio is proving its relevance more than ever today, offering a unique opportunity to improve care for millions of patients while reducing healthcare system costs."
***
About Mauna Kea Technologies
Mauna Kea Technologies is a global medical device company that manufactures and sells Cellvizio®, the real-time in vivo cellular imaging platform. This technology uniquely delivers in vivo cellular visualization which enables physicians to monitor the progression of disease over time, assess point-in-time reactions as they happen in real time, classify indeterminate areas of concern, and guide surgical interventions. The Cellvizio® platform is used globally across a wide range of medical specialties and is making a transformative change in the way physicians diagnose and treat patients. For more information, visit www.maunakeatech.com.
Disclaimer
This press release contains forward-looking statements about Mauna Kea Technologies and its business. All statements other than statements of historical fact included in this press release, including, but not limited to, statements regarding Mauna Kea Technologies' financial condition, business, strategies, plans and objectives for future operations are forward-looking statements. Mauna Kea Technologies believes that these forward-looking statements are based on reasonable assumptions. However, no assurance can be given that the expectations expressed in these forward-looking statements will be achieved. These forward-looking statements are subject to numerous risks and uncertainties, including those described in Chapter 2 of Mauna Kea Technologies' 2024 Annual Report filed with the Autorité des marchés financiers (AMF) on April 30, 2025, which is available on the Company's website (www.maunakeatech.fr), as well as the risks associated with changes in economic conditions, financial markets and the markets in which Mauna Kea Technologies operates. The forward-looking statements contained in this press release are also subject to risks that are unknown to Mauna Kea Technologies or that Mauna Kea Technologies does not currently consider material. The occurrence of some or all of these risks could cause the actual results, financial condition, performance or achievements of Mauna Kea Technologies to differ materially from those expressed in the forward-looking statements. This press release and the information contained herein do not constitute an offer to sell or subscribe for, or the solicitation of an order to buy or subscribe for, shares of Mauna Kea Technologies in any jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such jurisdiction. The distribution of this press release may be restricted in certain jurisdictions by local law. Persons into whose possession this document comes are required to comply with all local regulations applicable to this document.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Business Wire
22 minutes ago
- Business Wire
Yourgene Health Launches LightBench Discover
MANCHESTER, England--(BUSINESS WIRE)--Yourgene Health (part of the Novacyt group of companies), a leading international molecular diagnostics group, announces the launch of LightBench ® Discover, a high-precision 3-in-1 instrument for genomic research labs conducting long-read sequencing. LightBench Discover's 3-in-1 technology provides cost efficiencies, enhances quality control, simplifies workflows and delivers high-accuracy analytics which have all been designed around our customers' needs. The concept for the LightBench Discover was developed following a close collaboration with PacBio ®, where Yourgene Health became a PacBio Compatible Partner for the original LightBench in November 2023. As part of product development for LightBench Discover, Yourgene Health deployed prototype instruments into the field to gather customer feedback on user experience, develop protocols and run real-world samples to assess the instruments' performance. LightBench Discover is an integrated single benchtop solution that replaces the need for multiple instruments in labs conducting long-read HiFi sequencing, who need both large fragment analytics (larger than 20 kilobases) and DNA size selection. In addition, LightBench Discover also delivers fluorometric quantification. Researchers benefit from a cost-effective, high-performance system that enhances efficiency, whilst eliminating the need to invest in multiple instruments with separate service contracts and software platforms. The product has extended capabilities (compared to the original LightBench) for large fragment analytics up to 150 kilobases, along with size selection (powered by Ranger ® Technology) and quantification functions, making it ideal for research applications utilising long-read sequencing on the PacBio Revio ® or Vega ™ systems. Today, the Company has released the Technical Note showcasing data from its collaborator, The CoLab at the HudsonAlpha Institute for Biotechnology in Alabama, US. The Technical Note will be hosted on the Company's website and on the PacBio Compatible Partners webpage Lyn Rees, CEO of Novacyt, commented: 'The product development and launch of LightBench Discover is a significant achievement for the Novacyt team, and I would like to congratulate everyone for their efforts. LightBench Discover's 3-in-1 technology provides cost efficiencies, enhances quality control, simplifies workflows and delivers high-accuracy analytics which have all been designed around our customers' needs. This new offering from Novacyt will only further strengthen our existing partnerships and keep us at the forefront of genomic research.' Please contact Codon Communications for high-resolution images.
Business Wire
27 minutes ago
- Business Wire
Mark43 Co-Founder and President Matt Polega Appointed Managing Director UK to Lead Regional Expansion
MANCHESTER, England--(BUSINESS WIRE)--Mark43, the leading platform for intelligent policing operations, today announced the appointment of its Co-Founder and President Matt Polega as Managing Director UK. Polega is relocating to the UK to lead on-the-ground operations. This strategic move underscores Mark43's commitment to delivering innovative policing technology across the UK. 'As one of our co-founders, Matt has made an impact across every team at Mark43,' said Bob Hughes, CEO of Mark43. 'His leadership in delivering for our first UK customer, Cumbria Constabulary, has laid the foundation for long-term success and strong product-market fit in the region. His move comes at a pivotal moment in Mark43's growth, reinforcing our commitment to UK policing and our growing partner ecosystem. The demand for modern technology in policing is clear, and we're uniquely positioned to meet it as a trusted partner. We're thrilled to have Matt leading this essential work.' 'Thirteen years ago, we founded Mark43 to fundamentally transform public safety operations through modern technology,' said Matt Polega, Co-Founder, President, and Managing Director UK. 'Expanding that mission to the UK is a personal and professional milestone. I'm committed to supporting UK forces in meeting today's and tomorrow's policing challenges with the same innovation, partnership, and operational excellence that have defined Mark43 since day one.' 'Matt's appointment underscores Mark43's commitment to supporting UK police forces,' said Sir George Hamilton, former Chief Constable of the Police Service of Northern Ireland and Strategic Policing Advisor to Mark43. 'As a co-founder, Matt has been with Mark43 since day one, helping shape its mission and growth from the ground up. The company has already demonstrated its value through a successful deployment with Cumbria Constabulary, and under Matt's leadership, it is well-placed to continue delivering meaningful results as forces modernize to meet the evolving challenges of UK community safety.' This announcement follows a successful DDaT Forum hosted by Mark43 in London, which brought together over one-third of the country's police forces, alongside government representatives and senior policing leaders. It also follows the rapid expansion of Mark43's UK-based team, welcoming the brightest minds in engineering, customer success and implementation to innovate and accelerate delivery for UK policing. 'Over a decade ago, we launched our first Mark43 customer, the Metropolitan Police Department in Washington, D.C. It's been incredibly rewarding to see the impact of our technology benefitting police forces across the U.S. I'm thrilled to bring that experience to the UK,' said Polega. 'I look forward to continue partnering with UK forces to meet their evolving needs, strengthen collaboration and drive impact through our cloud-native technology.' Polega will continue to serve as Co-Founder, President, and Head of Marketing, Communications, and Enablement at Mark43. As Managing Director UK, Polega will be responsible for Mark43's operational excellence, strategic growth, partnerships and customer delivery throughout the region, reinforcing Mark43's role as the leading technology partner for police forces across the UK. To learn more, visit .
Business Wire
28 minutes ago
- Business Wire
CyberCube and Munich Re: Joint experts publish report to advance the insurance industry's understanding of systemic cyber risks
LONDON--(BUSINESS WIRE)--CyberCube and Munich Re, both leading providers in their field of cyber risk, analytics and insurance, have published the main findings of a joint study on severe cyber accumulation events and the relative resiliency of organizations to systemic events due to effective mitigation measures. The survey gathered insights from 93 seasoned cybersecurity professionals. The results provide a nuanced view of how systemic cyber events might unfold and of the factors that drive wide variation in risk exposure across firms: Widespread Malware Risk According to the majority of responding experts, a severe malware event could infect a quarter of all systems worldwide, but they agreed in that case only 15% may be fully compromised. Experts do not see an event where more than 50% of the world's systems are completely compromised. Based on the experts' judgement, another event on the scale of WannaCry and NotPetya would not be seen as surprising. Patch management, network segmentation, and data backups are identified as the most effective mitigations that organizations have against widespread malware attacks. When done effectively, such mitigations can reduce the chance of being affected by a widespread malware attack by 50% to 80% and reduce the financial impacts from such an event by a similar amount. Cloud Risk Cybersecurity experts expect broad cloud outages to last hours to days; outages beyond 72 hours are considered unlikely but not impossible. Findings show at least a medium level of dependency on cloud services across most industries with companies' business-critical operations increasingly reliant on them. Reliance tends to decrease with increasing company size. Financial losses scale with cloud outage duration: Respondents reported that a single-day outage of their most critical Cloud Service Provider (CSP) would likely result in a financial loss equal to 1% of their yearly revenue. Variation in losses reflect differences in dependency on the cloud, based on an organization's size, sector, and contingency planning. The most effective mitigation against cloud outages is to establish a multi-region architecture with the CSPs used for critical business applications. Having multiple CSPs was not found to be effective; the option to transfer service from one CSP to another during an outage was seen as unfeasible. Cyber Experts surveyed rate Azure, AWS and Google as the best prepared to mitigate against a major cloud outage and to recover from such an event. Emerging and Systemic Risks Experts believe that new technologies will begin to affect the threat landscape at about the same pace that they are being adopted in cybersecurity practices. According to cybersecurity experts, in the near term Industrial and Consumer Internet of Things (IoT) devices pose the biggest concern. Large Language Models (LLMs) are regarded as having an impact now while Artificial General Intelligence (AGI) is seen as a greater concern in five or more years. A fundamental challenge in cyber risk modeling is the deficiency of concrete tail-risk events, such as systemic malware or multi-region cloud outages. The joint survey represents the best attempt to parameterize plausible worst-case scenarios and establish expert consensus. Its objective was to advance market understanding, particularly concerning risk mitigation strategies for systemic cyber events. The results add credibility to CyberCube's model forecasts and further improve Munich Re's internal model and accumulation risk understanding. Jon Laux, Vice President of Analytics at CyberCube, said: "By sharing the findings of our study on systemic cyber risks, we aim to provide a more nuanced view of how systemic cyber events might unfold and the factors that drive wide variation in risk exposure across firms.' Stephan Brunner, Senior Cyber Actuary at Munich Re, said: 'Our ambition is to improve the understanding of possible extreme malware and cloud events alongside the effectiveness of mitigation measures by sharing the insights of our study. In collaboration, Munich Re aims to further strengthen expertise on systemic cyber risks and advance cyber accumulation modeling." The research has contributed to a more refined understanding of the relative resiliency of organizations to systemic events and the key variables that influence an organization's ability to withstand such incidents. These findings represent an important input into CyberCube's and Munich Re's evolving view of cyber risk and help inform ongoing enhancements to their modeling approach. CyberCube has incorporated these insights into Version 6 of its risk aggregation platform, Portfolio Manager. Modeling cyber accumulation is a joint effort across the entire insurance industry. For this reason, the key findings of the survey are being published to foster dialogue in the market. This study is the third of its kind, CyberCube and Munich Re plan to conduct another study in 2026. Interested cybersecurity experts are invited to participate. Read the report summarising the full study here – Key insights into systemic cyber risk CyberCube is the leading provider of software-as-a-service cyber risk analytics to quantify cyber risk in financial terms. Driven by data and informed by insight, we have harnessed the power of artificial intelligence to supplement our multi-disciplinary team. Our clients rely on our solutions to make informed decisions about managing and transferring cyber risks. We unpack complex cyber threats into clear, actionable strategies, translating cyber risk into financial impact on businesses, markets, and society as a whole. T he CyberCube platform was established in 2015 within Symantec and now operates as a standalone company. Our models are built on an unparalleled ecosystem of data and validated by extensive model calibration, internally and externally. CyberCube is the leader in cyber risk quantification for the insurance industry, serving over 100 insurance institutions globally. The company's investors include Forgepoint Capital, HSCM Bermuda and Morgan Stanley Tactical Value. For more information, please visit or email info@ Munich Re is one of the world's leading providers of reinsurance, primary insurance and insurance-related risk solutions. Munich Re is globally active and operates in all lines of the insurance business. Since it was founded in 1880, Munich Re has been known for its unrivalled risk-related expertise and its sound financial position. Munich Re leverages its strengths to promote its clients' business interests and technological progress. Moreover, Munich Re develops covers for new risks such as rocket launches, renewable energies, cyber risks and artificial intelligence. In the 2024 financial year, Munich Re generated insurance revenue of €60.8bn and a net result of €5.7bn. The Munich Re Group employed about 44,000 people worldwide as at 31 December 2024. For more information, please visit
